cbdMD Inc (YCBD) Stock AnalysisYCBDStock AnalysiscbdMD Inc

cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. It operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms. It operates in the Healthcare sector (PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS industry).

cbdMD Inc (YCBD) is not a strong buy right now due to its ongoing financial struggles, despite some positive indicators. The current price is $0.50, and the forward P/E ratio is extremely high at 714.29, indicating that the stock is overvalued based on future earnings expectations. Additionally, the stock has experienced a year-to-date change of -56.90%, reflecting significant declines in value. While the gross margin is relatively strong at 53.29%, the company continues to report net losses, with a net income of -$876,783 in Q2 2026. The main risk is the high forward P/E ratio, suggesting that expectations for future profitability may not be met, leading to further declines in stock price.